Baseline characteristics
| . | UCB (n = 1441) . | 7/8 BM (n = 172) . |
|---|---|---|
| Recipient age, median (interquartile range), y | 7 (3-11) | 10 (6-14) |
| Males | 831 (58) | 109 (63) |
| Female donor–to–male recipient | 400 (28) | 53 (31) |
| Disease status prior to HCT | ||
| ALL CR1 | 288 (20) | 30 (17.5) |
| ≥CR2 | 606 (42) | 78 (45) |
| AML CR1 | 281 (20) | 30 (17.5) |
| ≥CR2 | 266 (18) | 34 (20) |
| Time from diagnosis to HCT, median (interquartile range), mo | 14 (5-32) | 18 (6-37) |
| ATG/alemtuzumab used | 862 (60) | 91 (53) |
| ATG* | 851 (99) | 63 (69) |
| Alemtuzumab | 11 (1) | 28 (31) |
| Conditioning regimen | ||
| Cy + TBI ± other | 920 (64) | 122 (71) |
| Bu + Cy/Mel ± other | 353 (24) | 25 (14) |
| Others† | 168 (12) | 25 (15) |
| GVHD prophylaxis | ||
| CNI + MMF ± others (not Cy, MTX) | 582 (40) | 20 (11) |
| CNI + MTX ± others (not Cy, MMF) | 209 (15) | 135 (79) |
| CNI ± steroids | 557 (39) | 10 (6) |
| Others ± CNI | 72 (5) | 7 (4) |
| Missing | 21 (1) | 0 |
| Karnofsky/Lansky performance score‡ | ||
| ≥90 | 1166 (81) | 139 (81) |
| <90 | 225 (16) | 18 (10) |
| Donor-recipient CMV serostatus | ||
| −/− | 672 (47) | 49 (29) |
| −/+ | 747 (52) | 47 (27) |
| +/− | 0 | 25 (15) |
| +/+ | 0 | 40 (23) |
| Missing | 22 (1) | 11 (6) |
| Recipient race, ethnicity | ||
| White, non-Hispanic | 843 (59) | 101 (59) |
| White, Hispanic | 242 (17) | 28 (16) |
| Nonwhite, non-Hispanic | 245 (17) | 32 (19) |
| Nonwhite, Hispanic | 21 (1) | 1 (<1) |
| Missing | 90 (6) | 10 (6) |
| Year of HCT | ||
| 2000-2003 | 296 (20) | 50 (29) |
| 2004-2007 | 398 (28) | 86 (50) |
| 2008-2011 | 533 (37) | 26 (15) |
| 2012-2014 | 214 (15) | 10 (6) |
| Follow-up, median (range), mo | 71 (3-198) | 96 (6-196) |
| . | UCB (n = 1441) . | 7/8 BM (n = 172) . |
|---|---|---|
| Recipient age, median (interquartile range), y | 7 (3-11) | 10 (6-14) |
| Males | 831 (58) | 109 (63) |
| Female donor–to–male recipient | 400 (28) | 53 (31) |
| Disease status prior to HCT | ||
| ALL CR1 | 288 (20) | 30 (17.5) |
| ≥CR2 | 606 (42) | 78 (45) |
| AML CR1 | 281 (20) | 30 (17.5) |
| ≥CR2 | 266 (18) | 34 (20) |
| Time from diagnosis to HCT, median (interquartile range), mo | 14 (5-32) | 18 (6-37) |
| ATG/alemtuzumab used | 862 (60) | 91 (53) |
| ATG* | 851 (99) | 63 (69) |
| Alemtuzumab | 11 (1) | 28 (31) |
| Conditioning regimen | ||
| Cy + TBI ± other | 920 (64) | 122 (71) |
| Bu + Cy/Mel ± other | 353 (24) | 25 (14) |
| Others† | 168 (12) | 25 (15) |
| GVHD prophylaxis | ||
| CNI + MMF ± others (not Cy, MTX) | 582 (40) | 20 (11) |
| CNI + MTX ± others (not Cy, MMF) | 209 (15) | 135 (79) |
| CNI ± steroids | 557 (39) | 10 (6) |
| Others ± CNI | 72 (5) | 7 (4) |
| Missing | 21 (1) | 0 |
| Karnofsky/Lansky performance score‡ | ||
| ≥90 | 1166 (81) | 139 (81) |
| <90 | 225 (16) | 18 (10) |
| Donor-recipient CMV serostatus | ||
| −/− | 672 (47) | 49 (29) |
| −/+ | 747 (52) | 47 (27) |
| +/− | 0 | 25 (15) |
| +/+ | 0 | 40 (23) |
| Missing | 22 (1) | 11 (6) |
| Recipient race, ethnicity | ||
| White, non-Hispanic | 843 (59) | 101 (59) |
| White, Hispanic | 242 (17) | 28 (16) |
| Nonwhite, non-Hispanic | 245 (17) | 32 (19) |
| Nonwhite, Hispanic | 21 (1) | 1 (<1) |
| Missing | 90 (6) | 10 (6) |
| Year of HCT | ||
| 2000-2003 | 296 (20) | 50 (29) |
| 2004-2007 | 398 (28) | 86 (50) |
| 2008-2011 | 533 (37) | 26 (15) |
| 2012-2014 | 214 (15) | 10 (6) |
| Follow-up, median (range), mo | 71 (3-198) | 96 (6-196) |
Unless otherwise indicated, data are n (%).
Bu, busulfan; CMV, cytomegalovirus; CNI, calcineurin inhibitor; Cy, cyclophosphamide; Mel, melphalan; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.
One patient received ATG and alemtuzumab.
Five patients had unknown conditioning regimens.
The Lansky scale was used for 99% of the recipients younger than 16 years, whereas the Karnofsky scale was used for 94% of the recipients aged 16 to 17 years.